Clinical Trials
16 trialsNCT05701527 2026-02-05
A Study of EBC-129 in Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 1 Recruiting
NCT05036434 2026-01-23
ACCOMPLISH
National Cancer Center, Korea
Phase 2 Active not recruiting
NCT07349303 2026-01-21
NEOPRIME
Vastra Gotaland Region
Phase 2 Recruiting
NCT07136545 2025-09-10
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
Taipei Veterans General Hospital, Taiwan
Phase 1/2 Recruiting
NCT05304546 2025-07-22
MK3475-C01
Sheba Medical Center
Phase 2 Completed
NCT06670911 2025-02-24
ACCESS-I
Instituto Nacional de Cancer, Brazil
Phase 2 Recruiting
NCT02521844 2024-10-08
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 1 Active not recruiting
NCT06249854 2024-10-01
Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer
Korea Institute of Oriental Medicine
Phase 2 Recruiting
NCT02697630 2023-12-08
PEMDAC
Vastra Gotaland Region
Phase 2 Completed
NCT05832827 2023-10-23
Artemis
National Cancer Center, Japan
Phase 2 Recruiting
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting
NCT05551767 2022-09-23
Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer
City Clinical Oncology Hospital No 1
Phase 2 Unknown
NCT05025813 2022-08-01
DESQUAMATE
Queensland Health
Phase 2 Recruiting
NCT02938624 2021-12-14
MK3475-223
Sheba Medical Center
Phase 1 Completed
NCT03975036 2019-06-05
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
Henan Cancer Hospital
Phase 2/3 Unknown
NCT02430363 2016-02-24
Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
Medical Research Council
Phase 1/2 Unknown